---
title: Umlaut.bio
date: 2024-08-13T07:12:04Z
modified: 2026-08-12T09:10:32Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/umlaut-bio/"
type: portfolio
status: publish
excerpt: ""
wpid: 116330
language:
  - English
post_translations:
  - pll_66bb07418c2a2
branchen22:
  - Oncology
sectors:
  - Pharmaceuticals
focus_areas:
  - Oncology
timestamp: 2026-08-12T09:10:32Z
tags:
  - English
  - pll_66bb07418c2a2
  - Oncology
  - Pharmaceuticals
---

## Beschreibungstext

Umlaut.bio GmbH develops small molecules that are intended to be used as first-in-class therapeutics against a variety of diseases. The focus is on the “umlauts” of the genetic code – chemically modified RNA nucleotides. These play a crucial role in gene regulation and are of great importance, for example, in cancer cells. There, modified tRNAs protect protein-coding mRNAs from degradation and thus promote tumor growth. Therapeutic modalities that specifically address this mechanism could be able to selectively prevent the growth of cancer cells. This approach promises a disruptive novel form of cancer therapy that could offer a new, gentler treatment option for many patients.

## Unternehmenswebsite

> [Home](https://umlaut.bio/)

## Adresse

Umlaut.bio GmbH
Nikola-Tesla-Str.1
D-69124 Heidelberg
Germany

## Kontakt

Array